子宫颈癌血清肿瘤标志物与放疗后的预后
Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
作者信息
Sproston A R, Roberts S A, Davidson S E, Hunter R D, West C M
机构信息
Cancer Research Campaign Department of Experimental Radiation Oncology, Paterson Institute for Cancer Research, Manchester, UK.
出版信息
Br J Cancer. 1995 Dec;72(6):1536-40. doi: 10.1038/bjc.1995.543.
A study was made of the prognostic value of measurements of pretreatment serum marker levels in patients with carcinoma of the uterine cervix undergoing radiotherapy. The markers studied were carcinoma antigen 125 (CA125), squamous cell carcinoma antigen (SCC) and tissue polypeptide antigen (TPA). The levels of all three markers increased with disease stage. In a univariate analysis stratifying patients according to either median values or cut-off levels representing the top of the normal range, pretreatment levels predicted patient survival (follow-up times 1-4 years). In a multivariate analysis, disease stage was the most important prognostic variable and, after allowing for stage, only CA125 was a significant independent predictor of treatment outcome. These data suggest that, in carcinoma of the cervix treated with radiotherapy, pretreatment measurements of CA125, but not SCC and TPA, may have a role to play in defining prognosis.
对接受放射治疗的子宫颈癌患者进行了一项关于治疗前血清标志物水平测量的预后价值研究。所研究的标志物为癌抗原125（CA125）、鳞状细胞癌抗原（SCC）和组织多肽抗原（TPA）。所有这三种标志物的水平均随疾病分期增加。在单因素分析中，根据中位数或代表正常范围上限的临界值对患者进行分层，治疗前水平可预测患者生存率（随访时间1至4年）。在多因素分析中，疾病分期是最重要的预后变量，在考虑分期因素后，只有CA125是治疗结果的显著独立预测指标。这些数据表明，在用放射治疗的子宫颈癌中，治疗前测量CA125而非SCC和TPA可能在确定预后方面发挥作用。
Zotero 插件